IGF-1 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-04 and is reviewed periodically as new material appears.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Because ovulation is triggered by a surge in estradiol levels at mid-cycle, estrogen exposure during elagolix therapy might be greater around this time in some women. In addition to its activity as a GnRH antagonist, elagolix is a weak to moderate inducer of CYP3A and an inhibitor of P-glycoprotein. As a result, elagolix may affect the metabolism and/or transport of other medications, and this may contribute to drug interactions with elagolix.
Low-velocity: Less than 335 m/s (1,100 ft/s) Low velocity wounds are typical of small caliber handguns. They do not usually cause extensive soft tissue damage, and in the Gustilo open fracture classification are classified as Type 1 or 2 wounds.
In the United States, an all-out effort for making atomic weapons was begun in late 1942. This work was taken over by the U.S. Army Corps of Engineers in 1943, and known as the Manhattan Engineer District. The top-secret Manhattan Project, as it was colloquially known, was led by General Leslie R. Groves. Among the project's dozens of sites were: Hanford Site in Washington, which had the first industrial-scale nuclear reactors and produced plutonium; Oak Ridge, Tennessee, which was primarily concerned with uranium enrichment; and Los Alamos, in New Mexico, which was the scientific hub for research on bomb development and design. Other sites, notably the Berkeley Radiation Laboratory and the Metallurgical Laboratory at the University of Chicago, played important contributing roles. Overall scientific direction of the project was managed by the physicist J. Robert Oppenheimer. In July 1945, the first atomic explosive device, dubbed "The Gadget", was detonated in the New Mexico desert in the Trinity test. It was fueled by plutonium created at Hanford. In August 1945, two more atomic devices – "Little Boy", a uranium-235 bomb, and "Fat Man", a plutonium bomb – were used against the Japanese cities of Hiroshima and Nagasaki.
==== Dopamine receptor agonists ==== Apomorphine (Apofin; CHF-1526) – non-selective dopamine receptor agonist and other actions [330] Apomorphine subcutaneous (APO-go; Apokinon; Apokyn; Apomine; Britaject; KW-6500; Li Ke Ji; Movapo; Onapgotm; SPN-830) – non-selective dopamine receptor agonist and other actions [331] Bromocriptine (Parlodel) – dopamine D2-like receptor agonist and other actions Cabergoline (Dostinex) – dopamine D2-like receptor agonist and other actions Dihydroergocryptine (DHEC; Almirid; Cripar) – dopamine D2-like receptor agonist and other actions Lisuride (Dopergin) – dopamine D2-like receptor agonist and other actions Pergolide (Permax) – dopamine D2-like receptor agonist and other actions Piribedil (Trivastal, Pronoran) – dopamine D2-like receptor agonist and other actions Pramipexole (BI-Sifrol; Daquiran; Mirapex; Mirapexin; Pexola; Sifrol; SND-919; SND-919Y) – dopamine D2, D3, and D4 receptor agonist [332] Ropinirole (Adartrel; Repreve; Requip) – dopamine D2, D3, and D4 receptor agonist [333] Ropinirole (Requip CR; Requip LP; Requip XL; Requip XR; SKF-101468A) – dopamine D2, D3, and D4 receptor agonist [334] Ropinirole transdermal (Haruropi Tape; HP-3000) – non-selective dopamine receptor agonist and other actions [335] Rotigotine transdermal (Leganto; N-0437; N-0923; Neupro; Neupro Patch; Nubrenza; SPM-962) – non-selective dopamine receptor agonist and other actions [336] Talipexole (BHT-920; Domin) – dopamine D2 receptor agonist and α2-adrenergic receptor agonist [337]
== Analysis and characterization == Numerous destructive and non-destructive evaluation (NDE) methods exist for characterizing coatings. The most common destructive method is microscopy of a mounted cross-section of the coating and its substrate. The most common non-destructive techniques include ultrasonic thickness measurement, X-ray fluorescence (XRF), X-Ray diffraction (XRD), photothermal coating thickness measurement and micro hardness indentation. X-ray photoelectron spectroscopy (XPS) is also a classical characterization method to investigate the chemical composition of the nanometer thick surface layer of a material. Scanning electron microscopy coupled with energy dispersive X-ray spectrometry (SEM-EDX, or SEM-EDS) allows to visualize the surface texture and to probe its elementary chemical composition. Other characterization methods include transmission electron microscopy (TEM), atomic force microscopy (AFM), scanning tunneling microscope (STM), and Rutherford backscattering spectrometry (RBS). Various methods of Chromatography are also used, as well as thermogravimetric analysis.
Sources: en.wikipedia.org
=== Functional categorization === Nonsense mutations include stop-gain and start-loss. Stop-gain is a mutation that results in a premature termination codon (a stop was gained), which signals the end of translation. This interruption causes the protein to be abnormally shortened. The number of amino acids lost mediates the impact on the protein's functionality and whether it will function whatsoever. Stop-loss is a mutation in the original termination codon (a stop was lost), resulting in abnormal extension of a protein's carboxyl terminus. Start-gain creates an AUG start codon upstream of the original start site. If the new AUG is near the original start site, in-frame within the processed transcript and downstream to a ribosomal binding site, it can be used to initiate translation. The likely effect is additional amino acids added to the amino terminus of the original protein. Frame-shift mutations are also possible in start-gain mutations, but typically do not affect translation of the original protein. Start-loss is a point mutation in a transcript's AUG start codon, resulting in the reduction or elimination of protein production. Missense mutations code for a different amino acid. A missense mutation changes a codon so that a different protein is created, a non-synonymous change. Conservative mutations result in an amino acid change. However, the properties of the amino acid remain the same (e.g., hydrophobic, hydrophilic, etc.) At times, a change to one amino acid in the protein is not detrimental to the organism as a whole.
Models Four-door saloon (called the Protegé in North America, 323S in Europe, 323 Protegé in Australia, 323 Lantis/Familia in Indonesia, Allegro in Colombia, Artis in Chile and Étude in South Africa) Three-door coupé hatchback (Familia Neo in Japan, 323C in Europe and 323 in Canada) Three-door hatchback (called the 323P in Europe)
In the medical field of immunology, nanoCLAMP (CLostridal Antibody Mimetic Proteins) affinity reagents are recombinant 15 kD antibody mimetic proteins selected for tight, selective and gently reversible binding to target molecules. The nanoCLAMP scaffold is based on an IgG-like, thermostable carbohydrate binding module family 32 (CBM32) from a Clostridium perfringens hyaluronidase (Mu toxin). The shape of nanoCLAMPs approximates a cylinder of approximately 4 nm in length and 2.5 nm in diameter, roughly the same size as a nanobody (PDB: 2W1Q). nanoCLAMPs to specific targets are generated by varying the amino acid sequences and sometimes the length of three solvent exposed, adjacent loops that connect the beta strands making up the beta-sandwich fold, conferring binding affinity and specificity for the target.
===== North America ===== Canada - DMT is classified as a Schedule III drug under the Controlled Drugs and Substances Act, but is legal for religious groups to use. In 2017 the Santo Daime Church Céu do Montréal received religious exemption to use ayahuasca as a sacrament in their rituals. United States - DMT is classified in the United States as a Schedule I drug under the Controlled Substances Act of 1970. In 2019, it was decriminalized, along with other naturally derived psychedelics, in the city of Oakland after a campaign by Decriminalize Nature.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.